» Articles » PMID: 37062016

Recent Advances in CAR T-cell Therapy for Lymphoma in China

Overview
Specialty Oncology
Date 2023 Apr 16
PMID 37062016
Authors
Affiliations
Soon will be listed here.
Abstract

Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy, radiotherapy, and other advanced therapeutics, including rituximab or immune checkpoint inhibitors, have improved the prognosis in recent decades, there are still a number of patients with relapsed or refractory (R/R) lymphoma with a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy has provided a curative option for patients with relapsed or refractory lymphoma. Numerous clinical trials have been conducted worldwide and presented inspiring results that give insight into this breakthrough therapy. The development of cancer cell therapy in China has been rapid in the past years and dominates the field with the USA. This review aims to summarize the published results of CAR T-cell therapy alone or in combination with other therapies in mainland China, both in R/R NHL and R/R HL.

Citing Articles

Broadening the horizon: potential applications of CAR-T cells beyond current indications.

Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A Front Immunol. 2023; 14:1285406.

PMID: 38090582 PMC: 10711079. DOI: 10.3389/fimmu.2023.1285406.

References
1.
Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova Y . The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018; . DOI: 10.1111/ejh.13080. View

2.
Zeng C, Cheng J, Li T, Huang J, Li C, Jiang L . Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020; 22(3):166-171. DOI: 10.1016/j.jcyt.2020.01.008. View

3.
Wang C, Wu Z, Wang Y, Guo Y, Dai H, Wang X . Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clin Cancer Res. 2016; 23(5):1156-1166. DOI: 10.1158/1078-0432.CCR-16-1365. View

4.
Chiarle R, Podda A, Prolla G, Gong J, Thorbecke G, Inghirami G . CD30 in normal and neoplastic cells. Clin Immunol. 1999; 90(2):157-64. DOI: 10.1006/clim.1998.4636. View

5.
Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M . Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2016; 52(2):216-221. DOI: 10.1038/bmt.2016.213. View